Feature

Cancer patients report delays in treatment because of COVID-19


 

Taking action

“ACS CAN is working every day to make clear to Congress and the administration the real and immediate challenges cancer patients and survivors face during this pandemic,” said Brooks-Coley.

With nearly 50 other professional and advocacy groups, ACS CAN has sent letters to congressional leadership and the Secretary of the Department of Health & Human Services asking them to make policy changes that would help patients.

The proposed action points include having insurers allow patients to use providers who are out of network if necessary; waiving site-specific precertification and prior authorization for cancer treatment; utilizing shared decision making between patients and providers in deciding whether to use home infusion without pressure from the insurer; allowing patients to obtain 90-day supplies of medication; increasing funding for state Medicaid programs and assistance for those who have lost employee-sponsored coverage; and improving telehealth services.

“We urge Congress and the administration to keep the needs of cancer patients and survivors in mind as they continue to address the public health crisis,” she said.

This article first appeared on Medscape.com.

Pages

Recommended Reading

Managing pediatric heme/onc departments during the pandemic
AVAHO
Home-based chemo skyrockets at one U.S. center
AVAHO
When to treat, delay, or omit breast cancer therapy in the face of COVID-19
AVAHO
Cancer prevalence among COVID-19 patients may be higher than previously reported
AVAHO
Treating rectal cancer in the COVID-19 era: Expert guidance
AVAHO
ASCO announces its own COVID-19 and cancer registry
AVAHO
ASH tackles COVID-19 with hematology-related FAQ, promotes new registries
AVAHO
Severe COVID-19 may lower hemoglobin levels
AVAHO
Cancer care ‘transformed in space of a month’ because of pandemic
AVAHO
Can convalescent plasma treat COVID-19 patients?
AVAHO